Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Raptiva: Round up the usual suspects

Many compounds developed initially for rheumatoid arthritis are also tested in psoriasis, and vice versa. The reason: T cells appear to play a role in both diseases. But that doesn't mean compounds that work in one disease also work in the other, for reasons that are not yet clear. Such was the case with Raptiva efalizumab from Xoma Inc. and Genentech Inc. Last week, the partners halted a Phase

Read the full 697 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers